Our Featured Experts

Haythem Y. Ali, MD
Fred Saad, MD
Dr. Saad on Results of Radium-223 Trial in Prostate Cancer
Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.
Oncology Specialists
Publication Bottom Border
Border Publication